Xenome gets acute
Wednesday, 19 November, 2008
Private Brisbane biotech Xenome has expanded its protein chemistry portfolio by licensing peptide technology from Flinders University.
The IP relates to two peptides identified by Flinders researchers as candidates for blocking cell surface receptors involved in acute pancreatitis.
The receptors are activated by the peptide galanin, normally involved in the regulation of the release of neurotransmitters and hormones.
Xenome, which is in early stage trials of cone shell based venom peptides for acute and chronic pain, will pay Flinders milestone payments and royalties. It plans to modify the structure of the peptides to develop their capabities as drug candidates.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
